Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0N4OW
|
||||
| Former ID |
DAP000018
|
||||
| Drug Name |
Vasopressin
|
||||
| Synonyms |
Leiormone; Pitressin; Pituitrin; Tonephin; Vasopressina; Vasopressine; Vasopressins; Vasopressinum; American Pharmaceutical Brand of Vasopressin; American Regent Brand of Vasopressin; Antidiuretic Hormones; Antidiuretic hormone; Beta Hypophamine; Inyectable de vasopresina; Monarch Brand of Vasopressin; Solute injectable de vasopressine; Vasopressin Monarch Brand; Vasopressin injection; Vasopressina [DCIT]; Vasopressini injectio; ADH (hormone); Beta-Hypophamine; Inyectable de vasopresina [INN-Spanish]; Pitressin (TN); Solute injectable de vasopressine [INN-French]; Vasopressin (USP); Vasopressini injectio [INN-Latin]; Parke-Davis Brand of Vasopressin (USP); Vasopressin (JP15/USP)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Enuresis; Polyuria; Diabetes insipidus [ICD9: 250, 253.5, 307.6, 588.1, 788.30, 788.42; ICD10:E08-E13, E23.2, F98.0, N25.1] | Approved | [1], [2] | ||
| Therapeutic Class |
Vasoconstrictor Agents
|
||||
| Company |
Astellas Pharma
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C46H65N15O12S2
|
||||
| InChI |
InChI=1S/C46H65N15O12S2/c47-27-22-74-75-23-33(45(73)61-17-5-9-34(61)44(72)56-28(8-4-16-53-46(51)52)39(67)54-21-37(50)65)60-43(71)32(20-36(49)64)59-40(68)29(14-15-35(48)63)55-41(69)31(18-24-6-2-1-3-7-24)58-42(70)30(57-38(27)66)19-25-10-12-26(62)13-11-25/h1-3,6-7,10-13,27-34,62H,4-5,8-9,14-23,47H2,(H2,48,63)(H2,49,64)(H2,50,65)(H,54,67)(H,55,69)(H,56,72)(H,57,66)(H,58,70)(H,59,68)(H,60,71)(H4,51,52,53)/t27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
|
||||
| InChIKey |
KBZOIRJILGZLEJ-LGYYRGKSSA-N
|
||||
| CAS Number |
CAS 11000-17-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| SuperDrug ATC ID |
H01BA01
|
||||
| SuperDrug CAS ID |
cas=000050577
|
||||
| Target and Pathway | |||||
| Target(s) | Vasopressin V2 receptor | Target Info | Agonist | [3] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Vasopressin-regulated water reabsorption | |||||
| Pathway Interaction Database | Arf6 trafficking events | ||||
| PathWhiz Pathway | Vasopressin Regulation of Water Homeostasis | ||||
| Reactome | Vasopressin-like receptors | ||||
| G alpha (s) signalling events | |||||
| Vasopressin regulates renal water homeostasis via Aquaporins | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Regulation of Water Balance by Renal Aquaporins | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia. J Pharmacol Sci. 2009 Jan;109(1):53-9. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2168). | ||||
| REF 3 | Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.